Press Release

Optibrium™ today announced a collaboration with Enamine. The collaboration provides StarDrop™ users with easy access to EnamineStore, a database of their commercially available screening compounds and chemical building blocks. StarDrop has been developed to connect seamlessly with a wide variety of internal and external informatics systems and this latest partnership further extends the wealth of information available to users through StarDrop and its capabilities for small molecule design, optimisation and data analysis in drug discovery.

StarDrop provides free access to the Enamine database to easily search for commercially available compounds and building blocks. Enamine has over 3.3 million screening compounds and a further library of 7.8 million building blocks available to order from EnamineStore. The link enables users not only to search for specific compounds, but also find those that are structurally similar to their most interesting hits and leads or contain relevant substructures. This provides an invaluable tool for researchers to quickly enrich the understanding of their chemical structure-activity relationships.

Enamine and TBD Biodiscovery have entered into a collaboration agreement. The partnership aims to manage the transition of chemical synthesis of novel intermediates from laboratory to bulk scale under GMP standards utilizing Enamine’s know-how and process development expertise. This will help researchers meet the manufacturing feasibility criteria required for drug candidate selection, providing a rapid and cost effective scaled supply of new compounds.

Enamine Ltd., a leading compound supplier and BioSolveIT GmbH, a premium provider of drug discovery software, today announced the availability of the next generation of REAL Space Navigator, an efficient search tool within the world’s largest purchasable chemical space. Originally launched in February this year, Version 2 of REAL Space Navigator now offers ‘search and find’ access to an incredible 3.8 billion small molecular weight compounds ready for purchase.

Enamine and ChemAxon today announced the launch of jointly-created online resource (available at EnamineStore.com) to allow researchers worldwide to explore the chemical space of REAL database. The resource is aimed to provide the drug discovery community with the efficient solutions in hit-to-lead development. The querying of the chemical space is empowered by ChemAxon’s proprietary fast similarity search tool – MadFast, delivering sub-second response against hundreds of millions of molecules.

Enamine and BioSolveIT today announced the launch of the ‘REAL Space Navigator’. Jointly developed, the new software tool capitalizes on Enamine’s REAL (readily accessible) virtual compound concept and provides efficient ‘search & find’ access to more than 640 million pharma-oriented molecules, to date the world's largest chemical space of commercially accessible compounds.

Enamine Ltd. has today announced that it has expanded its collaboration on ZINC, a comprehensive online database of purchasable compounds curated by the Irwin and Shoichet laboratories in the Department of Pharmaceutical Chemistry at the University of California, San Francisco (UCSF). Via ZINC, Enamine will provide researchers at UCSF and the global drug-discovery community with access to the company’s REAL database, a unique database of more than 300 million novel synthetically feasible chemical structures as an efficient source of potential new compounds for a breadth of drug discovery projects.

Diamond Light Source (Diamond) and the Structural Genomic Consortium (SGC) Oxford announced today that Enamine will become a key supplier of poised fragment and analogue libraries to its XChem facility. Enamine will offer a new generation of the hit-finding library, Diamond-SGC-iNEXT (DSI) Poised Library to enable fast and productive fragment-based lead discovery (FBLD).

Axxam S.p.A. and Enamine Ltd. announced the start of a Research Collaboration to enhance the Axxam small molecule screening library with the addition of a further set of compounds aimed at early-stage CNS drug discovery, achieving a total library size of ca. 280 000 compounds.

Enamine Ltd. and the European Molecular Biology Laboratory (EMBL) have agreed to establish a collaboration whereby Enamine provides library synthesis, medicinal chemistry and biological services for the discovery and development of novel small molecules against EMBL’s proprietary anti-cancer targets.

Enamine Ltd. has announced that it has agreed to expand its collaboration in early drug discovery with Actelion Pharmaceuticals, covering therapeutic areas including cardiovascular and central nervous system disorders, immunology, infectious diseases and oncology.

Enamine Ltd. and Danish biotech company Pcovery have announced that they have extended their collaboration for the discovery of new drugs for the treatment of invasive fungal infections and platform technology development.

Enamine Ltd., a chemical company, producer of building blocks and screening libraries, announced today that it had signed a collaboration agreement with small molecule design house FCH Group Ltd (FCH).

Enamine, ChemBridge Corporation, UORSY and FCH Group today announced launch of Chem-Space, a global e-procurement marketplace solution for searching, purchasing and selling chemical building blocks. The Chem-Space database currently encompasses over 15 million unique molecular building blocks, and is the world’s largest chemicals library.

Enamine is announcing today the expansion of its Purification and Analytical Units to enable synthesis of 30 000 high quality screening library compounds monthly. Such expansion represents the largest development to date of its library synthesis capabilities.

Following the success since 2012 the collaboration with Sanofi aiming at finding of new valuable hit series in most challenging screening campaigns has been extended.

Collaboration with BioVersys AG aiming at discovery of novel treatments against bacterial infections has been extended for the 4th consecutive year.

Axxam S.p.A., a contract research and discovery company, announced today that an entirely new generation screening collection is now available for drug discovery programs: AXX^DIV2.0 made up with 240 000 carefully selected small molecules.

Enamine and Exquiron are announcing a multi-year collaboration wherby Exquiron is acquiring a large screening compounds libraries from Enamine.

3D Diversity Set from Enamine, containg 50 000 drug-like compounds, has been selected by ChanTest for their dicovery services using powerful HTS of Ion Channels, GPCRs and Transporters in partnership with pharma and biotech companies.

A collaboration agreement has been signed between Enamine, the Medical Research Council Laboratory of Molecular Biology (MRC LMB), Cambridge, UK, and the Institute of Organic Chemistry and Biochemistry of the Academy of Sciences of the Czech Republic (IOCB), Prague, Czech Republic. The new alliance is aimed at discovering novel Rhomboid Protease inhibitors as potential drugs to treat infectious, parasitic, oncological, immune and cardiovascular diseases. Enamine will provide the MRC LMB and IOCB with access to its integrated drug discovery capabilities, including Molecular Modeling, Compound Library, Screening Assays, Hit Finding and Characterization, Hit to Lead Chemistry and ADMET. The three parties will seek to partner the small molecule inhibitors generated with pharmaceutical companies for onward clinical development. The collaboration agreement was negotiated by MRC Technology on behalf of MRC LMB.